As you explore your options for Acute Lymphoblastic Leukemia research, consider our MuPrime™ Models. These models employ tumor homografts, transplants of GEMM tumors into immunocompetent syngeneic hosts, providing a relevant and reliable research tool. Each model is distinguished by NRAS activating mutations, known for their relation to early relapse and chemoresistance, in addition to the inclusion of clinically significant fusion genes. Importantly, our tumor homografts maintain the original GEMM tumor driver mutations, offering robust and synchronous growth—an ideal match for in vivo pharmacology studies. Investigate the potential of the MuPrime™ Models as you plan your Acute Lymphoblastic Leukemia study. These models offer a research platform that is both scientifically rigorous and practically efficient.